Difamilast软膏治疗儿童特应性皮炎:III期随机双盲对照试验
第4周IGA成功率在两剂量组均显著高于溶媒组,EASI改善也更优,不良事件多为轻中度。
要点
- 两剂量组EASI较溶媒组更早改善,且差异维持至第4周。
- 不良事件多为轻中度,未报告严重事件或死亡。
主要发现
- 第4周EASI评分改善≥50%、≥75%和≥90%的患者比例在两剂量组均显著高于溶媒组。
- 两剂量组EASI评分第1周即显著低于溶媒组,且差异维持至第4周。
- 多数治疗中出现的不良事件为轻中度,未报告严重事件或死亡。
关键数值与推荐
- 主要终点为第4周IGA评分0或1且改善至少2级的患者百分比。
局限性
- 研究人群为日本儿童,外推至其他人群需谨慎。
- 随访期为4周,缺乏长期疗效与安全性数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In atopic dermatitis (AD), phosphodiesterase 4 (PDE4) inhibition reduces proinflammatory mediators and cytokines. Difamilast is a new selective PDE4 inhibitor. OBJECTIVES: To demonstrate the superiority of topical difamilast to vehicle in Japanese paediatric patients with AD. METHODS: This was a phase III randomized, double-blind, vehicle-controlled trial. Patients aged 2-14 years with an Investigator Global Assessment (IGA) score of 2 or 3 received difamilast 0·3% (n = 83), difamilast 1% (n = 85) or vehicle (n = 83) ointment twice daily for 4 weeks. RESULTS: The primary endpoint was the percentage of patients with an IGA score of 0 or 1 with improvement by at least two grades at week 4. The success rates in IGA score at week 4 were 44·6%, 47·1% and 18·1% in the difamilast 0·3%, difamilast 1% and vehicle groups, respectively. Both difamilast groups demonstrated significantly higher success rates in IGA score compared with vehicle at week 4 [difamilast 0·3% (P < 0·001); difamilast 1% (P < 0·001)]. Regarding secondary endpoints, improvements in Eczema Area and Severity Index (EASI; improvement of ≥ 50%, ≥ 75% and ≥ 90% in overall score) at week 4 were significantly higher in patients in the difamilast 0·3% and 1% groups than those in the vehicle group. EASI score in the difamilast 0·3% and 1% groups was significantly reduced compared with that of patients in the vehicle group at week 1. The significant difference between both the difamilast groups and the vehicle groups was maintained from week 1 through to week 4. Most treatment-emergent adverse events were mild or moderate, and no serious events or deaths were reported. CONCLUSIONS: Difamilast 0·3% and 1% ointments are superior to vehicle and well tolerated in Japanese paediatric patients with AD.
引用
- Saeki H, Baba N, Ito K, et al. Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial. Br J Dermatol. 2021. PMID: 34289086. doi:10.1111/bjd.20655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。